GlassScriptPhysician profile
Evelynne Zatta
NPI 1720780539
$1,885.35
in general payments reported to CMS, 2019-2025
25 companies · $575 in 2025
The $575 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $48.94 · 2023: $477 · 2024: $785 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.42 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $299.58 | 2024-2025 | |
| Boston Scientific Corporation | $234.65 | 2022-2025 | Avvigo Guidance System, Wolverine Coronary Cutting Balloon, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $232.27 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Gilead Sciences, INC. | $133.64 | 2025 | Yeztugo |
| Lilly USA, LLC | $129.82 | 2023-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $129.67 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $124.97 | 2024 | Nuzyra |
| Daiichi Sankyo INC. | $123.83 | 2024-2025 | Injectafer |
| Cardiva Medical, INC. | $103.44 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Astellas Pharma US INC | $84.75 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $45.33 | 2025 | Rexulti |
| Abbott Laboratories | $23.89 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $23.79 | 2023 | Auvelity |
| Irhythm Technologies, INC. | $21.56 | 2024 | Zio Xt Patch, Zio Monitor |
| Antares Pharma, INC. | $18.36 | 2025 | Xyosted |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $18.34 | 2025 | Flucelvax, Fluad |
| Phathom Pharmaceuticals, INC. | $17.67 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.69 | 2025 | |
| Shield Therapeutics INC | $15.81 | 2023 | Accrufer |
| Bard Peripheral Vascular, INC. | $15.62 | 2023 | Lutonix Drug Coated Balloon |
| Novo Nordisk INC | $14.87 | 2023 | |
| Pfizer INC. | $14.41 | 2024 | |
| Terumo Medical Corporation | $14.34 | 2023 | Angio-Seal |
| Supernus Pharmaceuticals, INC. | $14.23 | 2023 | Qelbree |
| Amgen INC. | $13.82 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelynne Zatta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.